$PCVX News

Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential

Vaxcyte to Participate in Upcoming Investor Conferences

Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now

Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments

Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials

Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage

Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Reported Earlier, Vaxcyte's VAX-31 Demonstrates Robust Immune Responses Across All 31 Serotypes In Lancet-Published Phase 1/2 Adult Study Versus Prevnar 20

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate